Kering SA (KER)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 214.95 |
|---|---|
| 52-week range | 203.20 – 348.88 |
| Return, 1 month / 3 months | −7.7% / −14.3% |
| Return, 1 year / 3 years | −31.2% / −38.7% |
| Trend | Below its 200-day average |
| RSI (14) | 42 |
| Volatility (1 year) | 41.6% |
| Worst drawdown (1 year) | -39.2% |
| Average daily value traded | 80.69M EUR |
| Dividend yield | 1.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Kering is a French luxury goods group based in Paris. It owns and develops a collection of fashion and leather goods houses, including Gucci, Saint Laurent, Bottega Veneta and Balenciaga, whose products range from handbags and shoes to ready-to-wear clothing and accessories. The group also operates in jewellery and eyewear through its houses. Its customers are affluent shoppers in luxury markets around the world, served through directly operated boutiques, department stores and online channels.
The shares are listed on the Euronext Paris in France under the code KER, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Kering SA (KER) trades on the Euronext Paris in France. It last closed at EUR 214.95 on 19 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 353 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 31.2% and over the last three months it fell 14.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 35 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -15.1% | ||
| From 52-week high | -36.7% | ||
| Momentum | 37 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -14.3% | ||
| 6-month return | -8.7% | ||
| 12-month return, skipping the last month | -25.4% | ||
| Risk (lower is better) | 45 · Weak | Volatile, with deep drawdowns. | |
| Volatility (1 year) | 41.6% | ||
| Worst drawdown (1 year) | -39.2% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 80.69M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 38 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.9% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Risk (lower is better): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.9% |
|---|---|
| 1 month | −7.7% |
| 3 months | −14.3% |
| 6 months | −8.7% |
| 1 year | −31.2% |
| 3 years | −38.7% |
| 5 years | −65.4% |
Signals
| 50-day / 200-day average | 236.49 / 253.16 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.24 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jun 2026 | EUR 2.7500 |
| 13 Jan 2026 | EUR 1.2500 |
| 5 May 2025 | EUR 4.0000 |
| 14 Jan 2025 | EUR 2.0000 |
| 2 May 2024 | EUR 9.5000 |
| 15 Jan 2024 | EUR 4.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.